2015

Home/Tag: 2015

Oramed to Present at the BIO CEO & Investor Conference

Company to present on February 10, 2015 JERUSALEM, February 5, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming 17th Annual BIO [...]

2018-05-30T17:04:23+00:00Categories: Press Releases|Tags: |

Oramed Pharmaceuticals Inc. Issues Letter to Shareholders

JERUSALEM, January 28, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), Dear Friends, Shareholders and Associates,  As we recently entered into the New Year, I thought this would be a good opportunity to reflect on the achievements of this past year while also looking [...]

2018-05-30T17:04:23+00:00Categories: Press Releases|Tags: |

Oramed Granted Patent in Israel for Oral Administration of GLP-1

JERUSALEM, January 16, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Israel Patent Office has granted the Company's patent for its invention, titled "Methods and Compositions for [...]

2018-05-30T17:04:24+00:00Categories: Press Releases|Tags: |

Oramed Pharmaceuticals at LD MICRO “Main Event” Micro-Cap Growth Conference on December 2, 2014

JERUSALEM, December 1, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (https://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Company management will participate in the upcoming LD MICRO "Main Event" Micro-Cap Growth Conference taking place from [...]

2018-05-30T17:04:24+00:00Categories: Press Releases|Tags: |

Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes

Conference Call Scheduled for Monday, November 3, 2014 at 10:00 a.m. Eastern time JERUSALEM, October 31, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP)(https://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announces that the company will host a conference [...]

2018-05-30T17:04:25+00:00Categories: Press Releases|Tags: |

Oramed to Present at the FireRock Annual Micro-Cap Conference

Company CEO to present on October 28, 2014 JERUSALEM, October 24, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (https://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company's CEO, Nadav Kidron will present at FireRock [...]

2018-05-30T17:04:25+00:00Categories: Press Releases|Tags: |

Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes

Demonstrates Proof-of-Concept for ORMD-0801 Oral Insulin to Reduce Exogenous Insulin Requirements JERUSALEM, October 22, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (https://www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today reported positive top-line clinical results from its [...]

2018-05-30T17:04:25+00:00Categories: Press Releases|Tags: |

Oramed to Present at Family Office & Wealth Management Conference

Company CEO to present on September 17, 2014 JERUSALEM, September 15, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (https://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the Company's CEO, Nadav Kidron will present at DC Finance's [...]

2018-05-30T17:04:26+00:00Categories: Press Releases|Tags: |